GMED GLOBUS MED INC revenue, earnings and financials

For the quarter ended June 30, 2026, GLOBUS MED INC reported revenue of $790M (up 5.9% from a year earlier), net income of $152M and diluted EPS of $1.10; over the last four quarters revenue was $3.14B and net income $535M; for the fiscal year ended December 2025 revenue was $2.94B, up 16.7% on the year before.

GMED annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.94B, gross profit n/a, operating income $480M, net income $538M (margin 18.3%), EPS $3.92
• Fiscal year ended Dec 2024: revenue $2.52B, gross profit n/a, operating income $166M, net income $103M (margin 4.1%), EPS $0.75
• Fiscal year ended Dec 2023: revenue $1.57B, gross profit $1.02B, operating income $133M, net income $123M (margin 7.8%), EPS $1.07
• Fiscal year ended Dec 2022: revenue $1.02B, gross profit $759M, operating income $228M, net income $190M (margin 18.6%), EPS $1.85
• Fiscal year ended Dec 2021: revenue $958M, gross profit $719M, operating income $172M, net income $149M (margin 15.6%), EPS $1.44

GMED quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $790M (up 5.9% year over year), net income $152M, EPS $1.10
• Quarter ended Mar 31, 2026: revenue $760M (up 27.0% year over year), net income $124M, EPS $0.90
• Quarter ended Dec 31, 2025 (from the annual report): revenue $826M (up 25.7% year over year), net income $141M, EPS $1.01
• Quarter ended Sep 30, 2025: revenue $769M (up 22.9% year over year), net income $119M, EPS $0.88
• Quarter ended Jun 30, 2025: revenue $745M (up 18.4% year over year), net income $203M, EPS $1.49
• Quarter ended Mar 31, 2025: revenue $598M (down 1.4% year over year), net income $75.5M, EPS $0.54
• Quarter ended Dec 31, 2024 (from the annual report): revenue $657M (up 6.6% year over year), net income $26.5M, EPS $0.19
• Quarter ended Sep 30, 2024: revenue $626M (up 63.1% year over year), net income $51.8M, EPS $0.38
• Quarter ended Jun 30, 2024: revenue $630M (up 115.9% year over year), net income $31.8M, EPS $0.23
• Quarter ended Mar 31, 2024: revenue $607M (up 119.3% year over year), net income −$7.12M, EPS −$0.05
• Quarter ended Dec 31, 2023 (from the annual report): revenue $617M (up 124.6% year over year), net income $15.0M, EPS $0.01
• Quarter ended Sep 30, 2023: revenue $384M (up 51.0% year over year), net income $998K, EPS $0.01
• Quarter ended Jun 30, 2023: revenue $292M (up 10.6% year over year), net income $57.7M, EPS $0.57
• Quarter ended Mar 31, 2023: revenue $277M (up 20.0% year over year), net income $49.1M, EPS $0.48
• Quarter ended Dec 31, 2022 (from the annual report): revenue $274M (up 9.8% year over year), net income $50.1M, EPS $0.48
• Quarter ended Sep 30, 2022: revenue $254M (up 10.6% year over year), net income $47.4M, EPS $0.47
• Quarter ended Jun 30, 2022: revenue $264M (up 5.0% year over year), net income $54.6M, EPS $0.53
• Quarter ended Mar 31, 2022: revenue $231M (up 1.4% year over year), net income $38.1M, EPS $0.37
• Quarter ended Dec 31, 2021 (from the annual report): revenue $250M, net income $15.1M, EPS $0.15
• Quarter ended Sep 30, 2021: revenue $230M, net income $47.2M, EPS $0.45

GMED cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $753M, share buybacks $300M
• Fiscal year ended Dec 2024: operating cash flow $521M, share buybacks $85.8M
• Fiscal year ended Dec 2023: operating cash flow $243M, share buybacks $226M
• Fiscal year ended Dec 2022: operating cash flow $178M, share buybacks $144M
• Fiscal year ended Dec 2021: operating cash flow $276M, share buybacks n/a

GMED balance sheet

• Jun 30, 2026: cash $508M, total assets $5.49B, total liabilities $720M, shareholders' equity $4.77B
• Mar 31, 2026: cash $561M, total assets $5.44B, total liabilities $707M, shareholders' equity $4.73B
• Dec 31, 2025: cash $526M, total assets $5.30B, total liabilities $730M, shareholders' equity $4.57B
• Sep 30, 2025: cash n/a, total assets $5.10B, total liabilities $697M, shareholders' equity $4.40B
• Jun 30, 2025: cash n/a, total assets $4.96B, total liabilities $665M, shareholders' equity $4.30B
• Mar 31, 2025: cash n/a, total assets $4.71B, total liabilities $623M, shareholders' equity $4.09B
• Dec 31, 2024: cash $784M, total assets $5.25B, total liabilities $1.07B, shareholders' equity $4.18B
• Sep 30, 2024: cash n/a, total assets $5.09B, total liabilities $1.02B, shareholders' equity $4.07B

What is GMED's revenue?

GLOBUS MED INC reported $3.14B of revenue over its last four quarters, through June 30, 2026.

Is GMED profitable?

Yes. GLOBUS MED INC earned $535M over the last four quarters.

What is GMED's EPS?

Diluted earnings per share over the last four quarters were $3.89; $1.10 in the latest quarter.

GMED ownership and insider trades · All stocks